These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10583021)

  • 21. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection.
    Timm U; Erdin R
    J Chromatogr; 1992 Feb; 593(1-2):63-8. PubMed ID: 1639913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
    Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
    J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA; Soares-da-Silva P
    Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
    J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
    Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
    Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
    Vieira-Coelho MA; Soares-da-Silva P
    Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
    Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
    Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic disposition of 14C-bromfenac in healthy male volunteers.
    Osman M; Chandrasekaran A; Chan K; Scatina J; Ermer J; Cevallos W; Sisenwine SF
    J Clin Pharmacol; 1998 Aug; 38(8):744-52. PubMed ID: 9725551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
    Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
    Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert.
    Khromova I; Rauhala P; Zolotov N; Männistö PT
    Neuroreport; 1995 May; 6(8):1219-22. PubMed ID: 7662912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.
    Wikberg T; Vuorela A; Ottoila P; Taskinen J
    Drug Metab Dispos; 1993; 21(1):81-92. PubMed ID: 8095232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolcapone increases maximum concentration of levodopa.
    Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
    J Neural Transm (Vienna); 2000; 107(1):113-9. PubMed ID: 10809409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.